Rise and fall of total mesorectal excision with lateral pelvic lymphadenectomy for rectal cancer: an updated systematic review and meta-analysis of 11,366 patients.
Gabriele AnaniaRichard Justin DaviesAlberto ArezzoFrancesco BagoliniVito D'AndreaLuigina GraziosiSalomone Di SaverioGeorgi PopivanovIsaac CheruiyotRoberto CirocchiAnnibale DoniniPublished in: International journal of colorectal disease (2021)
Our publication does not demonstrate that TME with LLND has any oncological advantage when compared to TME alone, showing that with the advent of neoadjuvant therapy, the advantage of LLND is lost. In this review, the most important bias is the heterogeneous characteristics of patients, cancer staging, different neoadjuvant therapy, different radiotherapy techniques and fractionation used in different studies. Higher rate of functional post-operative complications does not support routinely use of LLND.
Keyphrases
- rectal cancer
- locally advanced
- systematic review
- neoadjuvant chemotherapy
- lymph node
- end stage renal disease
- early stage
- ejection fraction
- chronic kidney disease
- prognostic factors
- papillary thyroid
- radiation therapy
- meta analyses
- prostate cancer
- lymph node metastasis
- risk factors
- sentinel lymph node
- patient reported outcomes
- pet ct
- bone marrow